Clinical Trials Browser

Phase 1/2 × Active not recruiting × sotorasib × Clear all

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT05074810 2026-01-12

RAMP203

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04892017 2025-10-10

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis